EYPT
EyePoint Pharmaceuticals Inc

8,670
Mkt Cap
$958.68M
Volume
1.13M
52W High
$14.91
52W Low
$3.91
PE Ratio
-3.87
EYPT Fundamentals
Price
$11.58
Prev Close
$11.51
Open
$11.30
50D MA
$12.76
Beta
1.32
Avg. Volume
1.42M
EPS (Annual)
-$2.32
P/B
4.02
Rev/Employee
$262,260.61
Loading...
Loading...
News
all
press releases
HC Wainwright Issues Optimistic Estimate for EYPT Earnings
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for shares of Eyepoint Pharmaceuticals in a report...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Earnings Results, Misses Expectations By $0.08 EPS
Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) released its earnings results on Wednesday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat·7d ago
News Placeholder
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Rating of "Moderate Buy" by Analysts
Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the firm...
MarketBeat·8d ago
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given New $39.00 Price Target at Royal Bank Of Canada
Royal Bank Of Canada lifted their target price on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an "outperform" rating in a research report on Thursday...
MarketBeat·8d ago
News Placeholder
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down Following Weak Earnings
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Down After Earnings Miss...
MarketBeat·9d ago
News Placeholder
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.39% and -85.07%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock?
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·2mo ago
News Placeholder
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -26.87% and -32.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +15.38% and +9.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Latest Ratings for EYPT DateFirmActionFromTo Nov 2021HC Wainwright & Co.MaintainsBuy May 2021HC Wainwright & Co.MaintainsBuy Jan 2021Cantor FitzgeraldInitiates Coverage OnOverweight View More...
Benzinga·1y ago

Latest EYPT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.